Skip to main content
SpringerLink
Log in

Potential drug–drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey

  • Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to determine the drug profile of patients with non-small cell lung cancer (NSCLC) and to identify potential drug–drug interactions (PDDIs) during hospitalization. In particular, PDDIs in categories X and D were determined.

Methods

This retrospective cross-sectional study was conducted in the oncology services of a university hospital between 2018 and 2021. PDDIs were evaluated using Lexicomp Drug Interactions® software included in UpToDate®.

Results

A total of 199 patients were included in the study. Polypharmacy was present in 92.5% of the patients and the median (min–max) number of drugs used was 8 (2–16). 32% of the patients had D and X PDDIs. A total of 16 PDDIs at risk grade X were found in 15 (7.5%) patients. A total of 81 PDDIs of risk grade D were found in 54 (27.1%) patients and a total of 276 PDDIs of risk grade C were identified in 97 (48.7%) patients. Anticancer drugs (p = 0.008), opioids (p = 0.046), steroids (p = 0.003), 5-HT3 receptor antagonists (p = 0.012), aprepitant (p = 0.025) and antihistamines (p < 0.001) were statistically more frequent among patients with PDDIs than among those without.

Conclusion

The results of our study indicated that polypharmacy and PDDIs are common in hospitalized patients with NSCLC cancer. The monitoring of medications is critical for maximizing therapeutic effects and minimizing side effects related to PDDIs. As a part of multidisciplinary team, clinical pharmacists can contribute significantly to preventing, detecting and managing PDDIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article.

References

  • Abunahlah N, Sancar M, Dane F, Özyavuz MK (2016) Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. Int J Clin Pharm 38:1464–1476

    CAS  PubMed  Google Scholar 

  • Ajimura CM, Jagan N, Morrow LE, Malesker MA (2018) Drug interactions with oral inhaled medications. J Pharm Technol 34(6):273–280

    CAS  PubMed  PubMed Central  Google Scholar 

  • Akiyoshi T, Ito M, Murase S, Miyazaki M, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H (2013) Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. Drug Metab Pharmacokinet 28(5):411–415

    CAS  PubMed  Google Scholar 

  • Alkan A, Yaşar A, Karcı E, Köksoy EB, Ürün M, Şenler FÇ, Ürün Y, Tuncay G, Ergün H, Akbulut H (2017) Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Supp Care Cancer 25:229–236

    Google Scholar 

  • Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB (2008) Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 267(1):133–164

    CAS  PubMed  Google Scholar 

  • BCCA protocol (2021) non-small cell lung cancer Available from: http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lung/LUAJPC_Protocol.pdf Accessed May 2023

  • Bektay MY, Seker Z, Eke HK, Turk HM, Izzettin FV (2022) Comparison of different decision support software programs in perspective of potential drug–drug interactions in the oncology clinic. J Oncol Pharm Pract. https://doi.org/10.1177/10781552221104814

    Article  PubMed  Google Scholar 

  • Bibi R, Azhar S, Iqbal A, Jabeen H, Kalsoom U-E, Iqbal MM, Nazeer M (2021) Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors. J Oncol Pharm Pract 27(7):1616–1622

    CAS  PubMed  Google Scholar 

  • Björkman IK, Fastbom J, Schmidt IK, Bernsten CB (2002) Drug—drug interactions in the elderly. Ann Pharmacother 36(11):1675–1681

    PubMed  Google Scholar 

  • Blower P, De Wit R, Goodin S, Aapro M (2005) Drug–drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol 55(2):117–142

    Google Scholar 

  • Cicin I, Oksuz E, Karadurmus N, Malhan S, Gumus M, Yilmaz U, Cansever L, Cinarka H, Cetinkaya E, Kiyik M (2021) Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. Health Econ Rev 11(1):1–12

    Google Scholar 

  • Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777–794

    CAS  PubMed  Google Scholar 

  • Delpeuch A, Leveque D, Gourieux B, Herbrecht R (2015) Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anti Res 35(1):457–460

    Google Scholar 

  • Faqeer N, Mustafa N, Abd Al-jalil N, Qur’an T, (2021) Impact of clinical pharmacists in an inpatient medical oncology service: a prospective study at a comprehensive cancer center in Jordan. J Oncol Pharm Pract 27(4):897–901

    PubMed  Google Scholar 

  • Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544

    PubMed  Google Scholar 

  • Hines LE, Murphy JE (2011) Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9(6):364–377

    CAS  PubMed  Google Scholar 

  • Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ (2020) Polypharmacy, inappropriate medication use, and drug interactions in older Korean Patients with cancer receiving first-line palliative chemotherapy. Oncologist 25(3):e502–e511

    CAS  PubMed  Google Scholar 

  • International Agency for Research on Cancer 2012 Estimated cancer incidence, prevalence and mortality worldwide in 2012. http://globocan.iarc.fr/Pages/online.aspx Accessed April 2023.

  • Jarzyna D, Jungquist CR, Pasero C, Willens JS, Nisbet A, Oakes L, Dempsey SJ, Santangelo D, Polomano RC (2011) American society for pain management nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs 12(3):118–145

    PubMed  Google Scholar 

  • Jazbar J, Locatelli I, Horvat N, Kos M (2018) Clinically relevant potential drug–drug interactions among outpatients: a nationwide database study. Res Social Adm Pharm 14(6):572–580

    PubMed  Google Scholar 

  • Laban A, Birand N, Chukwunyere U, Abdi A, Başgut B (2021) Evaluation of drug-drug interactions in cancer patients treated at a university hospital in North Cyprus using two interaction databases. Niger J Clin Pract 24(7):1067–1071

    CAS  PubMed  Google Scholar 

  • Lakkad M, Martin B, Li C, Harrington S, Dayer L, Painter JT (2023) The use of gabapentinoids and opioids and risk of developing opioid-induced respiratory depression among older breast cancer survivors with neuropathic pain. J Cancer Surviv. https://doi.org/10.1007/s11764-023-01338-9

    Article  PubMed  Google Scholar 

  • McIntyre A, Ganti AK (2017) Lung cancer—a global perspective. J Surg Oncol 115(5):550–554

    PubMed  Google Scholar 

  • Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373–1378

    PubMed  Google Scholar 

  • Moghaddas A, Adib-Majlesi M, Sabzghabaee AM, Hajigholami A, Riechelmann R (2021) Potential drug–drug Interactions in hospitalized cancer patients: a report from the Middle-East. J Oncol Pharm Pract 27(1):46–53

    PubMed  Google Scholar 

  • Nachimuthu S, Assar MD, Schussler JM (2012) Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf 3(5):241–253

    PubMed  PubMed Central  Google Scholar 

  • Occhipinti M, Brambilla M, Galli G, Manglaviti S, Prelaj A, Ferrara R, De Toma A, Beninato T, Zattarin E, Proto C (2021) 133P drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment. J Thorac Oncol 16(4):S769–S770

    Google Scholar 

  • Park JW, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY (2016) Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. J Cancer Res Clin Oncol 142:1031–1040

    CAS  PubMed  Google Scholar 

  • Patel P, Leeder JS, Piquette-Miller M, Dupuis LL (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 83(10):2148–2162

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rahman HH, NiemannD M-M (2022) Association between asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, and lung cancer in the US population. Environ Sci Pollut Res 30(8):1–12

    Google Scholar 

  • Ramsdale E, Mohamed M, Yu V, Otto E, Juba K, Awad H, Moorthi K, Plumb S, Patil A, Vogelzang N (2022) Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment. Oncologist 27(7):e580–e588

    PubMed  PubMed Central  Google Scholar 

  • Rashdan S, Yang H, Le T, Selby C, Gerber DE, Alvarez CA (2021) Prevalence and significance of potential pharmacokinetic drug–drug interactions among patients with lung cancer: implications for clinical trials. Clin Drug Investig 41:161–167

    PubMed  Google Scholar 

  • Reimche L, Forster AJ, Van Walraven C (2011) Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol 51(7):1043–1050

    CAS  PubMed  Google Scholar 

  • Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20(12):1907–1912

    CAS  PubMed  Google Scholar 

  • Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9(S2):16–23

    CAS  PubMed  Google Scholar 

  • Roblek T, Vaupotic T, Mrhar A, Lainscak M (2015) Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol 71:131–142

    CAS  PubMed  Google Scholar 

  • Rowinsky EK, Gilbert M, McGuire W, Noe D, Grochow L, Forastiere A, Ettinger D, Lubejko B, Clark B, Sartorius S (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9(9):1692–1703

    CAS  PubMed  Google Scholar 

  • Ruths S, Viktil KK, Blix HS (2007) Classification of drug-related problems. Tidsskr nor Laegeforen 127:3073–3076

    PubMed  Google Scholar 

  • Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6(7):546–558

    CAS  PubMed  Google Scholar 

  • Strandell J, Wahlin S (2011) Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. Eur J Clin Pharmacol 67:633–641

    CAS  PubMed  Google Scholar 

  • Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A (2021) Epidemiology of lung cancer. Contemp Oncol 25(1):45–52

    CAS  Google Scholar 

  • Turner JP, Jamsen KM, Shakib S, Singhal N, Prowse R, Bell JS (2016) Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer 24:1831–1840

    PubMed  Google Scholar 

  • Umar RM, Apikoglu-Rabus S, Yumuk PF (2020) Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm 42:652–661

    PubMed  Google Scholar 

  • Uptodate Lexicomp Drugs & Drug Interaction Available from: https://www.uptodate.com/home/drugs-drug-interaction Accessed January 2023

  • US Food and Drug Administration (2012) Docetaxel injection, solution for intravenous infusion. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201525s002lbl.pdf Accessed May 2023

  • US Food and Drug Administration (2020) Paclitaxel injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf. Accessed May 2023

  • Vella-Brincat J, Macleod A (2007) Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother 21(1):15–25

    PubMed  Google Scholar 

  • Yancik R (2005) Population aging and cancer: a cross-national concern. Cancer J 11(6):437–441

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to give a special thanks to Prof. Dr. Bilgen Başgut for providing help and statements that greatly improved the manuscript.

Funding

The authors received no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Suleyman Demirel University, Isparta, Turkey

    Aslınur Albayrak

  2. Faculty of Pharmacy, Suleyman Demirel University, Isparta, Turkey

    Tuğdenur Düzenli

  3. Department of Medical Oncology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey

    Erkan Kayıkçıoğlu

Authors
  1. Aslınur Albayrak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tuğdenur Düzenli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erkan Kayıkçıoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AA and EK: conceived the study, AA: designed the study, analyzed data and wrote the manuscript. AA, EK and TD: collected data. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Aslınur Albayrak.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Ethics committee approval was obtained from Suleyman Demirel Clinical Research Ethics Committee (Approval No: 272, Date: 28.09.2022).

Informed consent

Since it was a retrospective study, informed consent were not obtainable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albayrak, A., Düzenli, T. & Kayıkçıoğlu, E. Potential drug–drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey. J Cancer Res Clin Oncol 149, 9621–9627 (2023). https://doi.org/10.1007/s00432-023-04890-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-04890-0

Keywords

Search

Navigation